{"product_id":"immunocore-five-forces-analysis","title":"Immunocore Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eImmunocore’s Porter’s Five Forces snapshot highlights strong supplier and buyer dynamics, high regulatory and R\u0026amp;D barriers, intense rivalry in immuno-oncology, and moderate threat from new entrants and substitutes. This brief view surfaces key competitive pressures shaping its pipeline and commercial prospects. Unlock the full Porter’s Five Forces Analysis to explore force-by-force ratings, visuals, and strategic implications for investment or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CDMOs and biologics inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmTACs demand advanced peptide-protein engineering, GMP biologics production and sterile fill-finish, limiting the pool of qualified CDMOs and creating supplier concentration; industry surveys in 2023–24 found over 60% of biotech firms cited CDMO lead times as a primary constraint. Long tech transfers and capacity bottlenecks typically add 9–18 months to timelines, making dual-sourcing difficult. This raises switching costs and gives suppliers leverage over pricing and scheduling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary epitopes and discovery tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAccess to validated HLA-peptide targets, libraries and screening platforms is often held by niche licensors, creating dependence during discovery and lead optimization; biotech licensing royalties commonly range 2–6% which raises hold-up risk. Unique epitope IP and reagents limit alternatives and can slow programs. Immunocore has built internal discovery capabilities to mitigate supplier power, but gaps in rare-allele reagents and niche libraries persist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites and CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncology centers with uveal melanoma expertise are scarce—uveal melanoma incidence ~5.1 per million annually (~1,700 US cases\/year), concentrating patient pools and boosting site leverage. Site bandwidth and CRO quality directly affect enrollment speed and data integrity, with the global CRO market ~50 billion USD in 2023 concentrating capability. Preferred site relationships command favorable terms; competition for patients elevates supplier power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics and HLA typing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKIMMTRAK is HLA-A*02:01–restricted, so reliable HLA typing and a companion diagnostic are required; only a handful of regulatory-grade labs and IVD partners can support commercial-scale rollout, concentrating supplier leverage. Integration into clinical workflows and payer reimbursement pathways increases complexity and gives vendors outsized influence on timing and per-patient diagnostic costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHLA restriction: HLA-A*02:01 required\u003c\/li\u003e\n\u003cli\u003eSupplier concentration: few regulatory-grade providers\u003c\/li\u003e\n\u003cli\u003eOperational impact: workflow and reimbursement add delays\u003c\/li\u003e\n\u003cli\u003eSupplier leverage: can raise rollout timelines and diagnostic costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain logistics and specialty distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCold-chain logistics are critical for immunotherapies, many requiring 2–8°C or ultra-cold -80°C storage and just-in-time delivery to oncology centers. Specialized 3PLs and specialty pharmacies, notably McKesson, Cardinal Health and AmerisourceBergen, concentrate the channel and can negotiate premium fees and exclusivity. Service-level failures risk irreversible product loss and adverse patient outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict temps: 2–8°C or -80°C\u003c\/li\u003e\n\u003cli\u003eConcentrated 3PL\/specialty pharmacy network\u003c\/li\u003e\n\u003cli\u003eFailures cause total product loss\u003c\/li\u003e\n\u003cli\u003eProviders can charge premiums\/exclusivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration: CDMO delays +9-18m; \u003cstrong\u003e60%\u003c\/strong\u003e affected; CROs $50B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier concentration (CDMOs, niche licensors, 3PLs) gives high leverage—\u0026gt;60% of biotechs cited CDMO lead times in 2023–24; CDMO transfers add 9–18 months. Royalties for licensed libraries commonly 2–6%. CRO\/3PL market concentration (CROs ~$50B in 2023) and limited HLA-A*02:01 diagnostics amplify switch costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eLead-time impact\u003c\/td\u003e\n\u003ctd\u003e60% firms cite; +9–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/3PLs\u003c\/td\u003e\n\u003ctd\u003eMarket size\/concentration\u003c\/td\u003e\n\u003ctd\u003eCROs ~$50B (2023); top providers dominant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Immunocore, this Porter's Five Forces overview uncovers key competitive drivers, buyer and supplier influence on pricing and profitability, barriers deterring new entrants, and disruptive substitutes or emerging threats that could erode market share—ideal for investor decks, strategy reports, or academic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA single-sheet Porter's Five Forces for Immunocore that maps supplier\/customer bargaining, substitute\/entrant threats and competitive rivalry—delivering fast, actionable insight to cut strategic uncertainty and speed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated payers and HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational health systems, PBMs, and HTA agencies control access and pricing for Immunocore therapies, demanding robust overall survival (OS) benefit and detailed budget impact justifications. The three largest US PBMs (CVS Caremark, Express Scripts, Optum Rx) manage roughly 80% of prescription claims, enabling tough negotiations and formulary leverage. This concentration drives outcomes-based contracts and risk-sharing models. Renewals and indication expansions face rigorous HTA scrutiny and cost-effectiveness thresholds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital formularies and oncology networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge IDNs and cancer centers drive protocol and pathway adoption, with centralized P\u0026amp;T committees (typically 8–12 members) making inclusion decisions based on comparative efficacy, toxicity and logistics; many committees meet quarterly to reassess oncology formularies. Inclusion often requires head-to-head or real-world evidence; volume commitments can yield discounts often exceeding 20% in negotiated oncology contracts. Centralized review amplifies buyer leverage, pressuring pricing and access timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease patient pool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUveal melanoma is very rare (≈5–6 cases per million\/year; ~2,500 cases\/year in the US), concentrating expertise in a few centers that can sway adoption; roughly 45–50% of patients are HLA‑A*02:01 eligible for tebentafusp, reducing buyer breadth. Sparse therapeutic alternatives lower price sensitivity, but tiny patient volumes limit pricing headroom with large payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence expectations and real-world data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuyers increasingly demand robust post-approval evidence, QoL metrics and head-to-head data to justify premium pricing; in 2024 payers use such data to set rebates and coverage limits. Real-world performance can trigger contract renegotiations and formulary repositioning. Companion diagnostic accuracy directly shapes perceived value and uptake, while transparency of outcomes data determines access terms and placement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePost-approval evidence\u003c\/li\u003e\n\u003cli\u003eQoL \u0026amp; head-to-head data\u003c\/li\u003e\n\u003cli\u003eReal-world-driven renegotiation\u003c\/li\u003e\n\u003cli\u003eCompanion diagnostic accuracy\u003c\/li\u003e\n\u003cli\u003eData transparency → formulary\/access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching and sequencing dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cponcologists sequencing immunotherapies trials and liver-directed care exert moderate bargaining power over immunocore because iv delivery required monitoring create switching costs that are meaningful but not prohibitive. as of tebentafusp remains the first approved systemic therapy for metastatic uveal melanoma so clear survival or safety advantages reduce buyer leverage. high adverse-event burden logistical complexity raises demands pricing concessions support programs trial access.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSequencing control: clinicians guide therapy order\u003c\/li\u003e\n\u003cli\u003eSwitching costs: moderate due to IV\/monitoring\u003c\/li\u003e\n\u003cli\u003eSurvival\/safety: superior outcomes reduce buyer power\u003c\/li\u003e\n\u003cli\u003eAE\/logistics: increases concessions and service demands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/poncologists\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer leverage: PBMs cover \u003cstrong\u003e~80%\u003c\/strong\u003e; uveal ~\u003cstrong\u003e2,500\u003c\/strong\u003e\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers (PBMs\/HTAs) hold strong leverage, demanding OS, cost‑effectiveness and outcomes‑based contracts; top 3 US PBMs cover ~80% of claims. IDNs\/P\u0026amp;T committees and specialized centers concentrate adoption, driving \u0026gt;20% discounting and strict formulary rules. Small uveal melanoma population (~2,500 US cases; 45–50% HLA‑A*02:01) limits volume but reduces competition, keeping pricing tensions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS cases\u003c\/td\u003e\n\u003ctd\u003eIncidence\u003c\/td\u003e\n\u003ctd\u003e~2,500\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHLA eligibility\u003c\/td\u003e\n\u003ctd\u003eProportion\u003c\/td\u003e\n\u003ctd\u003e45–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eImmunocore Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis Immunocore Porter's Five Forces Analysis preview is the exact document you'll receive after purchase; no placeholders or mockups. The full analysis is fully formatted, comprehensive, and ready for immediate download and use once payment is completed. You’ll get this same file instantly—complete and professional.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162845917561,"sku":"immunocore-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/immunocore-five-forces-analysis.png?v=1762709931","url":"https:\/\/portersfiveforce.com\/products\/immunocore-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}